Latest update: July 2022 

With the world’s highest proportion of the elderly (nearly 30% in 2020), the number of patients with cancer and other diseases is expected to increase in Japan. It is the third largest pharmaceutical market in the world, and the biologically active substances (biopharmaceuticals) are considered to be the driving force behind innovation in this industry. In 2021, the Japanese biopharmaceutical market value was estimated at 2,1 trillion yen. Even though the pharmaceutical market growth is projected to be negative, the biopharmaceutical sector is expected to grow.

EU-Japan Centre, The Biopharmaceuticals sector in Japan, 2019
EU-Japan Centre, Latest trends in biotechnology research in Japan, 2021
JETRO, Life Science Report, 2022
International Trade Administration, Japan-Pharmaceuticals, 2022

> For more information about the Japanese pharmaceutical market, laws, and regulations, click here


Table of Contents

  • Collaborative Opportunities
  • Regenerative Medicine
  • Gene Therapy
  • Blood Substitutes
  • Vaccines
  • Antibody and Peptide-based Drugs
  • Biosimilars
  • Expert Reports & Webinars
  • Annual Report
  • Further Reading
  • Relevant Organisations and Trade Fairs
Please log in for full access
Subscribe to
our newsletters

The EU-Japan Centre currently produces 5 newsletters :

  • EU-Japan NEWS - our flagship newsletter covering the Centre's support services, information about EU (or Member States) - Japan cooperation
  • Japanese Industry and Policy News
  • “About Japan” e-News (Only available for EU companies / EU organisations)
  • Japan Tax and Public Procurement Weekly Tender Digest (Only available for EU companies / EU organisations)
  • Tech Transfer Helpdesk Newsletter
1 EUR = 166,528 JPY